养阴通络汤对原发性胆汁性胆管炎临床疗效及对细胞因子的影响

杨磊; 李莹; 袁星星; 李丹丹; 王炳予; 刘长发; 张雅丽

doi:10.3969/j.issn.1671-038X.2017.09.02

养阴通络汤对原发性胆汁性胆管炎临床疗效及对细胞因子的影响

- 1. 黑龙江省中医药科学院南岗分院消化科, 黑龙江哈尔滨 150001;
- 2. 黑龙江省中医药科学院三辅分院肾一科, 黑龙江哈尔滨 150036
基金项目:
国家中医药管理局科学技术专项课题 (No:2016ZX05)

黑龙江省博士后科研启动基金 (No::LBH-Q13156)

详细信息

通讯作者: 张雅丽,E-mail::zhangyl_2013@sina.com

中图分类号: R575.7

收稿日期: 2017-04-20

Effect of Yangyin Tongluo Decoction on primary biliary cholangitis and its influence on cytokines

- 1. Department of Gastroenterology, Heilongjiang Academy of Traditional Chinese Medicine, Harbin 150001, China;
- 2. Department of Nephrology, Heilongjiang Academy of Traditional Chinese Medicine, Harbin 150036, China

More Information

Corresponding author: ZHANG Ya-li, E-mail: zhangyl_2013@sina.com

Received Date: 20 April 2017

摘要

摘要: [目的]观察养阴通络汤对原发性胆汁性胆管炎患者临床疗效及血清细胞因子的影响。[方法]将符合诊断标准的78例原发性胆汁性胆管炎患者,按照随机数字表法分为对照组(39例)和治疗组(39例),其中对照组给予熊去氧胆酸治疗,治疗组在对照组的基础上给予养阴通络汤,2组疗程均治疗48周。分别观察2组患者治疗前、后临床症状,血清肝功能、肝纤维化四项及细胞因子水平。[结果]治疗组治疗总反应率为89.74%,治疗组明显优于对照组(P＜0.05);治疗组治疗12、24周中医症状积分较本组治疗前下降(P<0.05),疗程结束后中医症状积分较本组治疗前明显下降(P<0.01);2组治疗24周及疗程结束后组间比较,治疗组优于对照组(P<0.05);2组治疗12周后ALP、TBIL、AST、GGT与本组治疗前比较均下降(P<0.05);治疗12周后ALP、TBIL、AST、GGT组间比较,治疗组明显优于对照组(P<0.05),2组疗程结束后ALP组间比较,差异有统计学意义(P<0.01),疗程结束后TBIL、AST、GGT组间比较,差异有统计学意义(P<0.05);治疗组治疗后HA、PⅢP较本组治疗前明显下降(P<0.01),LN、Ⅳ-C较本组治疗前下降,(P<0.05);2组治疗后组间比较,治疗组明显优于对照组(P<0.05);治疗组治疗后IL-6、IL-17、IL-22、TNF-α水平较本组治疗前下降(P<0.05);2组治疗后组间比较,治疗组明显优于对照组(P<0.05)。[结论]养阴通络汤联合UCDA能够明显改善PBC肝功能,减轻肝纤维化程度,调节血清细胞因子水平,临床疗效显著。
- 养阴通络汤 /
- 熊去氧胆酸 /
- 原发性胆汁性胆管炎 /
- 细胞因子
Abstract: [Objective]To observe the clinical efficacy of Yangyin Tongluo decoction on patients with primary biliary cholangitis and its influence on serum cytokines.[Methods]78 patients with primary biliary cholangitis were divided into the control group(39 cases)and treatment group(39 cases)according to random number table.The control group was treated with Ursodeoxycholic acid capules and the treatment group was treated with Ursodeoxycholic acid capules combined with Yangyin Tongluo decoction,the course of treatment was 48 weeks in both groups.The clinical efficacy and serum liver function,liver fibrosis,cytokines factors were detected also.[Results]The total response rate of the treatment group was 89.74%,the treatment group was significantly better than the control group(P<0.05).In the treatment group,the TCMs symptom scores were lower at 12 and 24 weekend(P<0.05)and the TCMs symptom scores were significantly lower at the end of treatment(P<0.01),the treatment group was better than the control group at 24 and 48 weekend(P<0.05).ALP,TBIL,AST,GGT were decreased at 12 weekend in both groups(P<0.05)and the treatment group was significantly better than the control group(P<0.05).After the end treatment,the difference was statistically significant at ALP(P<0.01)while the difference was statistically significant on TBIL,AST,GGT(P<0.05).HA,PⅢP were significantly decreased after treatment(P<0.01)and LN、Ⅳ-C were decreased compared with before treatment(P<0.05);the treatment group was significantly better than the control group after treatment(P<0.05).After treatment,the levels of IL-6,IL-17,IL-22 and TNF-αwere lower than those before treatment(P＜0.05);the treatment group was significantly better than the control group after treatment(P<0.05).[Conclusion]Yangyin Tongluo decoction combined with UCDA can significantly improve the liver function of PBC,reduce the degree of liver fibrosis,regulate the level of serum cytokines.
- Yangyin Tongluo Decoction /
- ursodeoxycholic acid /
- primary biliary cholangitis /
- cytokine

HTML全文

参考文献(16)

[1]	段维佳, 田秋菊, 尤红, 等.原发性胆汁性胆管炎的研究进展[J].临床肝胆病杂志, 2016, 32 (11):1491-1496.
[2]	张爱平, 杨江华.原发性胆汁性胆管炎发病机制的研究进展[J].世界华人消化杂志, 2016, 24 (2):169-175.
[3]	徐莹, 慕永平, 刘平.刘平治疗原发性胆汁性肝硬化经验撷英[J].上海中医药杂志, 2015, 49 (12):1-4.
[4]	中华医学会肝病学分会.原发性胆汁性肝硬化 (又名原发性胆汁性胆管炎) 诊断和治疗共识 (2015)[J].临床肝胆病杂志, 2015, 31 (12):1980-1988
[5]	中国中西医结合学会肝病专业委员会.肝纤维化中西医结合诊疗指南[J].中西医结合肝病杂志, 2006, 16 (05):316-320.
[6]	邱德凯, 马雄主编.自身免疫性肝病基础与临床[M].上海:上海科学技术出版社, 2006:110-111, 191-192.
[7]	国家中医药管理局.中医病证诊断疗效标准[S].南京:南京大学出版社, 1994:10-11.
[8]	Boonstra K, Berers U, et al.Epidemiology of primary sclerosing cholangitis and primary biliary cirhosis:a systematic review[J].J Hepatol, 2012, 56 (5):1181-1188.
[9]	段维佳, 田秋菊, 尤红, 贾继东.原发性胆汁性胆管炎的研究进展[J].临床肝胆病杂志, 2016, (11):2062-2065.
[10]	彭桉平, 陈曲波, 等.原发性胆汁性肝硬化患者外周血Th22细胞水平的变化及意义[J].实用医学杂志, 2014, (12):1987-1989.
[11]	Lan RY, Salunga TL, Tsuneyama K, et al.Hepatic IL-17responses in human and murine primary biliary cirrhosis[J].J Autoimun, 2009, 32 (1):43-51.
[12]	王丹丹, 邓志华.原发性胆汁性肝硬化的诊断和治疗进展[J].国际消化病杂志, 2016, 54 (4):202-205+209.
[13]	Lammers WJ, Kowdley KV, van Bauren HR, et al.Predicting outcome in primary biliary cirrhosis[J].J Ann Hepatol, 2014, 13 (4):316-326.
[14]	蒲艳, 杨晋辉, 杨婧.原发性胆汁性肝硬化的治疗进展[J].世界华人消化杂志, 2014, 22 (34):5273-5278.
[15]	顾敏威, 张勇, 孙振宇.白芍总苷对大鼠体外循环后肝损伤的保护作用[J].世界华人消化杂志, 2015, 23 (25):3997-4004.
[16]	陆小华, 马骁, 王建, 等.赤芍的化学成分和药理作用研究进展[J].中草药, 2015, 46 (4):595-602.